Neurex (Citicoline Sodium)

Citicoline sodium supplies choline and cytidine, which are precursors for phosphatidylcholine synthesis and acetylcholine production. This promotes neuronal membrane stability, supports RNA synthesis, and enhances neurotransmission, contributing to neuroprotection and improved cognitive function after cerebral injury.

The appropriate dose of Neurex is determined by the prescribing clinician based on the patient’s condition, severity, and route of administration. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for citicoline sodium in pregnancy and lactation are limited. The product’s pregnancy category is unknown, so it should only be used if the potential benefit justifies any potential risk to the fetus or infant, and after consultation with a qualified healthcare professional.

To request Neurex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with other neuroprotective agents, citicoline sodium uniquely provides both choline and cytidine precursors, directly supporting membrane phospholipid synthesis and acetylcholine production. This dual mechanism distinguishes it from agents that act solely as antioxidants or excitatory blockers, offering a broader approach to neuronal recovery.

Neurex should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vials. Before administration, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

Neurex is supplied as a sterile injectable solution and may be given either intramuscularly or intravenously, depending on the clinical protocol. Administration should be performed by qualified healthcare personnel using aseptic technique and appropriate infusion or injection equipment.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, and rare occurrences of seizures. Patients should be monitored closely for any signs of these events, and treatment should be discontinued immediately if they occur.

Neurex should be avoided in individuals with known hypersensitivity to citicoline sodium or any excipients in the formulation. Caution is also advised for patients with uncontrolled hypertension, severe renal impairment, or those taking medications that could cause dangerous additive hypotensive effects.